Evidence map›Paper›PMID 31025169›Full record

ArticlePurinergic signalling2019

Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes.

Molhm Nassir, Uri Arad, Sang-Yong Lee, Shani Journo, Salahuddin Mirza, Christian Renn, Herbert Zimmermann, Julie Pelletier, Jean Sévigny, Christa E Müller and 1 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Molhm NassirDepartment of Chemistry, Bar-Ilan University, 52900, Ramat-Gan, Israel.
Uri AradDepartment of Rheumatology, Tel Aviv Medical Center and the Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Sang-Yong LeePharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Shani JournoDepartment of Rheumatology, Tel Aviv Medical Center and the Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Salahuddin MirzaPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Christian RennPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Herbert ZimmermannInstitute of Cell Biology and Neuroscience, Goethe-University, 60438, Frankfurt am Main, Germany.
Julie PelletierCentre de Recherche du CHU de Québec - Université Laval, Québec City, QC, Canada.
Jean SévignyCentre de Recherche du CHU de Québec - Université Laval, Québec City, QC, Canada.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Bilha FischerDepartment of Chemistry, Bar-Ilan University, 52900, Ramat-Gan, Israel. bilha.fischer@biu.ac.il.ORCID 0000-0001-8837-0978
University of Bonn · DEBar-Ilan University · ILTel Aviv University · ILUniversité Laval · CAGoethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overproduction of extracellular diphosphate due to hydrolysis of ATP by NPP1 leads to pathological calcium diphosphate (pyrophosphate) dihydrate deposition (CPPD) in cartilage, resulting in a degenerative joint disease that today lacks a cure. Here, we targeted the identification of novel NPP1 inhibitors as potential therapeutic agents for CPPD deposition disease. Specifically, we synthesized novel analogs of AMP (NPP1 reaction product) and ADP (NPP1 inhibitor). These derivatives incorporate several chemical modifications of the natural nucleotides including (1) a methylene group replacing the P

Indexed as

Adenosine DiphosphateAdenosine TriphosphateChondrocalcinosisChondrocytesEnzyme InhibitorsHumansOsteoarthritisPhosphoric Diester HydrolasesPyrophosphatasesAdenosine DiphosphateAdenosine Triphosphateectonucleotide pyrophosphatase phosphodiesterase 1Enzyme InhibitorsPhosphoric Diester HydrolasesPyrophosphatasesAcyclic nucleotideADP analogsAMP analogsCalcium pyrophosphate dihydrate (CPPD)Ecto-nucleotide pyrophosphatase/phosphodiesterase1 (NPP1)Human chondrocytes

Identifiers

PMID31025169
PMCPMC6635514
OpenAlexW4206958656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.